4-IODO-6-PHENYLPYRIMIDINE
|
|
|
- CAS号:
- 41270-96-6
- 英文名:
- 4-IODO-6-PHENYLPYRIMIDINE
- 英文别名:
- 4-IPP;MIF Antagonist III, 4-IPP;4-IODO-6-PHENYLPYRIMIDINE;Pyrimidine, 4-iodo-6-phenyl-;4-IPP (4-Iodo-6-phenylpyrimidine);MIF Antagonist III, 4-IPP - CAS 41270-96-6 - Calbiochem;Inhibitor,osteoclastogenesis,4IPP,MIF,4-IPP,inhibit,4 IPP,RANKL,osteoblast
- 中文名:
- 4-IODO-6-PHENYLPYRIMIDINE
- 中文别名:
- 化合物4-IPP;4-碘-6-苯基嘧啶;4-IPP,巨噬细胞迁移抑制因子(MIF)抑制剂
- CBNumber:
- CB1686643
- 分子式:
- C10H7IN2
- 分子量:
- 282.08
- MOL File:
- Mol file
|
|
|
4-IODO-6-PHENYLPYRIMIDINE化学性质
-
沸点:
-
380.2±30.0 °C(Predicted)
-
|
-
密度:
-
1.728±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
-20°C
-
|
-
溶解度:
-
DMSO: soluble10mg/mL (clear solution, warmed)
-
|
-
形态:
-
powder
-
|
-
酸度系数(pKa):
-
-0.54±0.17(Predicted)
-
|
-
颜色:
-
white to beige
-
|
-
InChIKey:
-
ZTCJXHNJVLUUMR-UHFFFAOYSA-N
-
|
4-IODO-6-PHENYLPYRIMIDINE性质、用途与生产工艺
4-IPP (4-Iodo-6-phenylpyrimidine)是 macrophage migration inhibitory factor (MIF) 的不可逆抑制剂，是MIF的特异性自杀底物。4-IPP可以抑制NF-κB配体（RANKL）诱导的破骨细胞的受体激活剂，并在体外增强成骨细胞介导的矿化和骨结节的形成。
4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity.
4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes.
4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation.
4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner.
4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption .
Cell Cytotoxicity Assay
|
Cell Line:
|
BMMs
|
|
Concentration:
|
0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM
|
|
Incubation Time:
|
24 hours, 72 hours
|
|
Result:
|
Inhibited osteoclastogenesis in a dose-dependent manner.
|
Western Blot Analysis
|
Cell Line:
|
BMMs
|
|
Concentration:
|
5 μM,10 μM, 20 μM
|
|
Incubation Time:
|
1 day, 3 days, 5 days
|
|
Result:
|
Inhibited RANKL-induced osteoclast differentiation and bone resorption.
|
4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation.
|
Animal Model:
|
8-weeks-old C57BL/6J male mice
|
|
Dosage:
|
1 mg/kg, 5 mg/kg
|
|
Administration:
|
Intraperitoneal injection; every 2 days; for 8 weeks
|
|
Result:
|
Alleviated OVX-induced osteoporosis.
|
4-IODO-6-PHENYLPYRIMIDINE
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-110063 | 4-IPP | | 1 mg | 400元 |
| 2024/04/30 | HY-110063 | 4-IODO-6-PHENYLPYRIMIDINE
4-IPP | 41270-96-6 | 5mg | 1150元 |
4-IODO-6-PHENYLPYRIMIDINE
生产厂家
41270-96-6, 4-IODO-6-PHENYLPYRIMIDINE 相关搜索:
- 药靶配体
- 4-IPP,巨噬细胞迁移抑制因子(MIF)抑制剂
- 4-碘-6-苯基嘧啶
- 化合物4-IPP
- 41270-96-6
- Inhibitor,osteoclastogenesis,4IPP,MIF,4-IPP,inhibit,4 IPP,RANKL,osteoblast
- 4-IPP (4-Iodo-6-phenylpyrimidine)
- Pyrimidine, 4-iodo-6-phenyl-
- MIF Antagonist III, 4-IPP - CAS 41270-96-6 - Calbiochem
- MIF Antagonist III, 4-IPP
- 4-IPP
- 4-IODO-6-PHENYLPYRIMIDINE